Biogen Inc. (BIIB), based in Cambridge, Massachusetts, has a market capitalization of approximately $33.3 billion. Founded in 1978, the biotechnology company discovers, develops, manufactures, and commercializes innovative medicines for neurological, neurodegenerative, autoimmune, and rare diseases, leveraging scientific research to improve patient outcomes and drive long-term growth.
BIIB is set to report its Q3 earnings on Wednesday, October 28, 2026, before the market opens. Ahead of the release, analysts expect the company to report diluted EPS of $2.10, down 56.3% from $4.81 in the year-ago quarter. That said, BIIB has exceeded Wall Street’s EPS estimates in each of the past four quarters, highlighting its consistent earnings performance.